The placebo effect in thyroid cancer: a meta-analysis

Area of Science:

• Oncology
• Clinical Trials
• Thyroid Cancer Research

Background:

• The natural history and therapy-free evolution of advanced thyroid malignancies, including differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC), remain poorly understood.
• Clinical trial placebo arms offer a unique opportunity to study the natural progression of these advanced cancers without therapeutic intervention.

Purpose of the Study:

• To systematically analyze the response rates, symptom progression, and adverse effects in patients with locally advanced or metastatic DTC and MTC who received a placebo in clinical trials.
• To establish a baseline understanding of disease behavior and patient outcomes in the absence of active treatment for advanced thyroid cancers.

Main Methods:

• A comprehensive meta-analysis was performed on data extracted from high-quality randomized controlled clinical trials identified through PubMed (MEDLINE) and SCOPUS searches up to September 2015.
• Studies including a placebo arm for patients with DTC or MTC were selected.
• Response rates, treatment adherence, and adverse events were analyzed using an empirical Bayesian random-effect model.

Main Results:

• Across five identified clinical trials, no complete response was observed in the placebo groups for either DTC or MTC.
• Partial response rates were 1.6% for DTC and 6.4% for MTC, while stable disease was observed in 40.5% of DTC patients and 53.9% of MTC patients.
• Disease control rates were 42.3% for DTC and 60.2% for MTC. Treatment discontinuation and dose reduction rates were relatively low.

Conclusions:

• This meta-analysis provides critical data on the efficacy and safety of placebo in advanced DTC and MTC, highlighting limited response and disease stabilization.
• The findings serve as a valuable benchmark for interpreting results from future clinical trials, particularly those lacking a placebo arm, and for understanding the natural history of these advanced thyroid cancers.